Scynexis (SCYX) Non-Current Deffered Revenue (2013 - 2025)
Scynexis (SCYX) posted Non-Current Deffered Revenue of $800000.0 for Q3 2025, up 60.0% on a QoQ basis from $500000.0 in Q2 2025, and down 38.46% year-over-year from $1.3 million in Q3 2024.
Scynexis (SCYX) Non-Current Deffered Revenue (2013 - 2025) Analysis & Trends
Scynexis' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $800000.0 for Q3 2025.
- Quarterly Non-Current Deffered Revenue fell 38.46% year-over-year to $800000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $800000.0 (down 38.46% YoY) and the FY2024 annual result came in at $1.3 million, down 52.55% from the prior year.
- Non-Current Deffered Revenue was $800000.0 for Q3 2025 at Scynexis, up from $500000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $2.7 million in Q4 2023 and bottomed at $500000.0 in Q2 2025.
- A 3-year average of $1.5 million and a median of $1.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue soared 59.39% — and 2025, when it sank 72.48%.
- Scynexis' Non-Current Deffered Revenue stood at $2.7 million in 2023, then tumbled by 52.55% to $1.3 million in 2024, then tumbled by 38.18% to $800000.0 in 2025.
- Business Quant data shows SCYX's Non-Current Deffered Revenue at $800000.0 in Q3 2025, $500000.0 in Q2 2025, and $1.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 1.29 Mn |
| Dec 31, 2024 | 1.29 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Dec 31, 2023 | 2.73 Mn |
| Sep 30, 2023 | 1.65 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2018 | 57,000.00 |
| Dec 31, 2017 | 121,000.00 |
| Jun 30, 2017 | 249,000.00 |
| Mar 31, 2017 | 20,000.00 |
| Dec 31, 2016 | 25,000.00 |
| Sep 30, 2016 | 442,000.00 |
| Jun 30, 2016 | 25,000.00 |
| Mar 31, 2016 | 571,000.00 |
| Dec 31, 2015 | 25,000.00 |
| Sep 30, 2015 | 699,000.00 |